Literature DB >> 18074866

Incidence of lymphomas in Poland. The national register data for 2006.

Krystyna Gałazka1, Joanna Szpor, Renata Maryniak, Włodzimierz Olszewski, Olga Mioduszewska, Jerzy Stachura.   

Abstract

In Poland, data on the incidence and mortality associated with malignancies are collected by the National Cancer Register (NCR). The Register is based on the International Classification of Diseases (ICD-10), which does not allow for assessing the incidence of lymphatic neoplasms classified according to the WHO classification system enforced since 2001. Under the National Program of Combating Neoplastic Diseases that focuses on detection and diagnosing malignant lymphomas in Poland in order to record and precisely classify lymphatic neoplasms, in 2006, the Haematopathological Section of the Polish Society of Pathologists, acting in collaboration with the Polish Lymphoma Study Group, initiated a nationwide register of lymphatic malignancies, a continuation of the Register of Lymphomas for the Province of Małopolska. The register not only renders epidemiological data more specific, but also allows for a comprehensive quality control.

Entities:  

Mesh:

Year:  2007        PMID: 18074866

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  2 in total

1.  Distribution of lymphomas in Poland according to World Health Organization classification: analysis of 11718 cases from National Histopathological Lymphoma Register project - the Polish Lymphoma Research Group study.

Authors:  Anan Szumera-Ciećkiewicz; K Gałązka; J Szpor; G Rymkiewicz; D Jesionek-Kupnicka; A Gruchała; B Ziarkiewicz-Wróblewska; G Poniatowska-Broniek; S Demczuk; M Prochorec-Sobieszek
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

2.  Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma.

Authors:  E Paszkiewicz-Kozik; J Kulik; A Fabisiewicz; A Tysarowski; E Kraszewska; J A Siedlecki; J Walewski
Journal:  Med Oncol       Date:  2008-05-10       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.